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Background
Soluble guanylate cyclase (sGC) is a central target of nitric
oxide (NO) action. sGC is a heterodimeric hemoprotein.
The ferrous heme efficiently traps NO and plays an inti-
mate role in activation of the enzyme to catalyse the con-
version of GTP to cGMP. sGC is also the target for
cardiovascular therapies involving small molecules that
stimulate sGC directly or activate oxidized or apo
sGC. Efforts to fully characterize sGC catalysis have
been hampered by the lack of structural information.
High-resolution structures of sGC fragments (domains)
have been determined and have provided important detail;
however, a structure of the full-length protein, an essential
piece of the puzzle, remains unsolved.
Results
Using hydrogen-deuterium exchange-mass spectrometry
(HDX-MS), higher order domain interactions have been
mapped [1]. HDX-MS revealed direct interactions between
the PAS domain and the heme-associated signaling helix of
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Figure 1 Domain organization of sGC subunits Each sGC subunit, a1 (grey) and b1 (tan), is composed of four modular domains. The H-NOX
domain of the b1 subunit contains the heme co-factor (red). Amino acid numberings approximate the boundaries of the b1 domains. The
H-NOX structure is modeled from a standalone H-NOX from Nostoc sp. PCC 7120 (33% identity, PDB: 2o09). The representative PAS domain is
from Nostoc punctiforme histidine kinase (35% identity, PDB: 2P04). The helical domain (PDB: 3HLS) and catalytic domain (PDB: 3UVJ) are
crystallized truncations of sGC from Rattus norvegicus and Homo sapiens, respectively.
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the H-NOX domain. Furthermore, interfaces between the
H-NOX and catalytic domains were mapped using domain
truncations and full-length sGC. The H-NOX domain
buries surfaces of the a1 catalytic domain proximal to the
cyclase active site, suggesting a signaling mechanism invol-
ving NO-induced de-repression of catalytic activity. This
method is now being extended to map the conformational
changes that take place in sGC with NO binding and other
small molecules that influence catalytic activity. In addition,
significant advances toward a full-length structure have
been obtained using single-particle electron microscopy.
Conclusion
Together these approaches define the architecture of the
sGC holoenzyme, revealing inter-domain interactions
responsible for communicating NO-occupancy from the
heme to the catalytic site. The resultant structural model
of sGC provides insight into the mechanisms of activation
of both NO and small molecule modulators.
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